# RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients

> **NCT01829802** · PHASE4 · UNKNOWN · sponsor: **Pedro Cahn** · enrollment: 50 (estimated)

## Conditions studied

- Chronic Infection With HIV

## Interventions

- **DRUG:** Ritonavir boosted Atazanavir
- **DRUG:** Raltegravir
- **DRUG:** TDF/FTC (or 3TC)

## Key facts

- **NCT ID:** NCT01829802
- **Lead sponsor:** Pedro Cahn
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-05
- **Primary completion:** 2017-10
- **Final completion:** 2017-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2017-01-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01829802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01829802, "RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT01829802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*